United Therapeutics Corporation Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
United Therapeutics (UTHR) Tops Q2 EPS by 76c, Sales Easily Beat
July 27, 2017 6:15 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.37, $0.76 better than the analyst estimate of $3.61. Revenue for the quarter came in at $444.6 million versus the consensus estimate of $391.53 million.
"Our second quarter total net revenues reached $445 million, our highest quarterly net revenue level ever,"... More
